» Articles » PMID: 26322669

HIV, Antiretroviral Therapy, and Hypertensive Disorders in Pregnancy: A Systematic Review and Meta-analysis

Overview
Date 2015 Sep 1
PMID 26322669
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There are data to suggest that infection with HIV or use of highly active antiretroviral therapy increases the risk of hypertensive disorders in pregnancy. This systematic review and meta-analysis aims to provide an overview of the research hitherto.

Methods: A systematic review of EMBASE, PubMed, and The Cochrane Library databases was conducted to obtain articles about the association between HIV in pregnancy and/or HIV therapy and the risk of developing pregnancy-induced hypertension (PIH), pre-eclampsia, eclampsia, or Hemolysis Elevated Liver enzymes Low Platelet count syndrome. Quality of articles was evaluated with an adapted Cochrane Collaboration bias assessment tool. Relative risks (RRs) were pooled with a random-effects meta-analysis weighted by the inverse of their variance.

Results: Of the 2136 articles screened, 28 studies were eligible for inclusion; 15 studies reported on the association with PIH, 16 on pre-eclampsia, 5 on eclampsia, and 3 articles on HIV therapy regimens. All articles had a high risk of bias, and between-study heterogeneity was considerable. Based on the meta-analysis, there does not seem to be an association between HIV and PIH [RR 1.26, 95% confidence interval (CI): 0.87 to 1.83, I = 78.6%], pre-eclampsia (RR 1.01, 95% CI: 0.87 to 1.18, I = 63.9%), or eclampsia (RR 1.61, 95% CI: 0.14 to 18.68, I = 97.0%). A meta-analysis of the association with HIV therapy and risk of hypertensive disorders in pregnancy could not be performed.

Conclusions: This meta-analysis shows no significant association between HIV positivity and PIH, pre-eclampsia, or eclampsia. However, the high risk of bias within most studies limits the strength of conclusions and well-designed studies are necessary to confirm or refute these findings.

Citing Articles

Challenges, risks, and opportunities of antiretroviral drugs in women of reproductive potential.

Henderson A, Cholli P, Lampe M, Kourtis A Expert Rev Anti Infect Ther. 2024; 22(4):153-167.

PMID: 38517686 PMC: 11287786. DOI: 10.1080/14787210.2024.2334054.


Cardiometabolic Health in Pregnancy and Postpartum: Findings From a Prospective Cohort Study in South Africa.

Bengtson A, Madlala H, Matjila M, Goedecke J, Cu-Uvin S, McGarvey S Open Forum Infect Dis. 2024; 11(3):ofae093.

PMID: 38481429 PMC: 10932940. DOI: 10.1093/ofid/ofae093.


Comparative risk of adverse perinatal outcomes associated with classes of antiretroviral therapy in pregnant women living with HIV: systematic review and meta-analysis.

Beck K, Cowdell I, Portwood C, Sexton H, Kumarendran M, Brandon Z Front Med (Lausanne). 2024; 11:1323813.

PMID: 38476445 PMC: 10927998. DOI: 10.3389/fmed.2024.1323813.


Antiretroviral Options and Treatment Decisions During Pregnancy.

Poliektov N, Badell M Paediatr Drugs. 2023; 25(3):267-282.

PMID: 36729360 DOI: 10.1007/s40272-023-00559-w.


Antiretroviral Therapy and Adverse Pregnancy Outcomes in People Living with HIV.

Eke A, Mirochnick M, Lockman S N Engl J Med. 2023; 388(4):344-356.

PMID: 36720135 PMC: 10400304. DOI: 10.1056/NEJMra2212877.